New Japanese Regenerative Medicine Legislation
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Mesoblast
Later from Mesoblast
- Half-Year Results & Strategic Update on Product Development
- Key mpc patents granted in united states and china
- Mesoblast Corporate Overview - CEO Message to AGM
- MSB Provides Corporate Strategy For Neurologic Product
- Positive Results in Phase 2 Lumbar Spinal Fusion Trial
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast